Dystrogen Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$1.09M
- Investors
-
2
Dystrogen Therapeutics General Information
Description
Developer of novel chimeric cell therapy designed to treat patients with Sarcopenia. The company's platform uses a proprietary chimeric cell technology platform, which focuses on treating patients with rare diseases such as Duchenne muscular dystrophy, sickle cell anemia, and neurodegenerative disorders, enabling patients with Sarcopenia and related rare diseases to effectively cure their diseases.
Contact Information
Website
www.dystrogen.comCorporate Office
- 1415 West 37th Street
- Chicago, IL 60609
- United States
Corporate Office
- 1415 West 37th Street
- Chicago, IL 60609
- United States
Dystrogen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Seed Round | 07-Aug-2019 | $1.09M | Completed | Clinical Trials - Phase 1 | ||
| 1. Corporate | 01-Jan-2019 | Completed | Clinical Trials - Phase 1 |
Dystrogen Therapeutics Comparisons
Industry
Financing
Details
Dystrogen Therapeutics Competitors (1)
One of Dystrogen Therapeutics’s competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA |
Dystrogen Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dystrogen Therapeutics Patents
Dystrogen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12337015-B2 | Myoblast chimeric cells (mccs) | Active | 14-Mar-2019 | ||
| US-20220160783-A1 | Myoblast chimeric cells (mccs) | Active | 14-Mar-2019 | ||
| US-20250345366-A1 | Myoblast chimeric cells (mccs) | Pending | 14-Mar-2019 | ||
| WO-2020186197-A1 | Myoblast chimeric cells (mccs) | Inactive | 14-Mar-2019 | A61K35/34 |
Dystrogen Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Dystrogen Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| StarFinder | Venture Capital | Minority | ||
| Polski Bank Komórek Macierzystych | Corporation | Minority |
Dystrogen Therapeutics FAQs
-
When was Dystrogen Therapeutics founded?
Dystrogen Therapeutics was founded in 2017.
-
Where is Dystrogen Therapeutics headquartered?
Dystrogen Therapeutics is headquartered in Chicago, IL.
-
What is the size of Dystrogen Therapeutics?
Dystrogen Therapeutics has 5 total employees.
-
What industry is Dystrogen Therapeutics in?
Dystrogen Therapeutics’s primary industry is Drug Discovery.
-
Is Dystrogen Therapeutics a private or public company?
Dystrogen Therapeutics is a Private company.
-
What is Dystrogen Therapeutics’s current revenue?
The current revenue for Dystrogen Therapeutics is .
-
How much funding has Dystrogen Therapeutics raised over time?
Dystrogen Therapeutics has raised $1.39M.
-
Who are Dystrogen Therapeutics’s investors?
StarFinder and Polski Bank Komórek Macierzystych have invested in Dystrogen Therapeutics.
-
Who are Dystrogen Therapeutics’s competitors?
Sarepta Therapeutics is a competitor of Dystrogen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
